Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effektivitet och säkerhet hos en drickbar näringskost för håravfall hos patienter som använder GLP-1/GIP-receptoragonister

1 oktober 2026 uppdaterad av: Olistic Research Labs S.L.

Utvärdering av effektiviteten och säkerheten hos ett drickbart kosttillskott för att förbättra håravfall hos patienter behandlade med GLP-1/GIP-receptoragonister: en dubbelblind, 1:1 randomiserad, placebokontrollerad studie.

The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

40

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Madrid
      • Madrid, Madrid, Spanien, 28006
        • Rekrytering
        • Grupo Dermatologico Y Estetico Pedro Jaen S.A.
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

35 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Female gender.
  • Age >35 years.
  • Initiation of treatment with a GLP-1/GIP agonist, or treatment duration < 3 months, as per routine clinical practice in the endocrinology clinic.
  • Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
  • Additional criteria to be included by the client.

Exclusion Criteria:

  • Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
  • Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
  • Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
  • Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
  • Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
  • Women who have used anti-hair loss products within the last 3 months.
  • Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).
  • Women who have undergone hair transplantation within the 18 months prior to study initiation.
  • Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.
  • Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.
  • Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.
  • Additional exclusion criteria to be specified by the sponsor.
  • Any condition that, in the investigator's opinion, makes participation in the study inappropriate.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placeboarm

Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.

Experimentell: Aktiv produktarm

Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Hair loss
Tidsram: From baseline to Day 180.

• Patient Reported Outcome using the Hair Shedding Scale: will assess the degree of hair loss among participants. On the day of the visit, they will be shown an A4 sheet with six ranges: between 1 (minimal shedding) to 6 (copious hair shedding).

Ref. Perera E and Sinclair R, 2017

From baseline to Day 180.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Hair loss
Tidsram: From baseline to Day 180.

Comb and Wash Test: this test will quantify the number of fallen hairs (outcome number of shed hairs). It will be carried out after refraining from washing the hair for 48 hours and combing the hair for 24 hours.

From baseline to Day 180.
Body composition
Tidsram: From baseline to Day 180.

Body weight (Kg). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Body composition
Tidsram: From baseline to Day 180.

BMI (Kg/m2). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Body composition
Tidsram: From baseline to Day 180.

Fat mass and fat-free mass percentages. Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Serum iron level
Tidsram: From baseline to Day 180.

Serum iron concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Ferritin level
Tidsram: From baseline to Day 180.

Serum ferritin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Transferrin level
Tidsram: From baseline to Day 180.

Serum transferrin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Transferrin saturation
Tidsram: From baseline to Day 180.

Transferrin saturation percentage calculated from iron metabolism parameters obtained from blood samples.

From baseline to Day 180.
Serum zinc level
Tidsram: From baseline to Day 180.

Serum zinc concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
25-hydroxyvitamin D level
Tidsram: From baseline to Day 180.

Serum 25-hydroxyvitamin D concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum folate level
Tidsram: From baseline to Day 180.

Serum folate concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Vitamin B12 level
Tidsram: From baseline to Day 180.

Serum vitamin B12 concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum albumin level
Tidsram: From baseline to Day 180.

Serum albumin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Thyroid-stimulating hormone (TSH) level
Tidsram: From baseline to Day 180.

Serum thyroid-stimulating hormone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Free thyroxine (free T4) level
Tidsram: From baseline to Day 180.

Serum free thyroxine concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Total testosterone level
Tidsram: From baseline to Day 180.

Serum total testosterone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Free testosterone level
Tidsram: From baseline to Day 180.

Serum free testosterone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Dehydroepiandrosterone sulfate (DHEA-S) level
Tidsram: From baseline to Day 180.

Serum dehydroepiandrosterone sulfate concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Sex hormone-binding globulin (SHBG) level
Tidsram: From baseline to Day 180.

Serum sex hormone-binding globulin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Fasting glucose level
Tidsram: From baseline to Day 180.

Fasting blood glucose concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Glycated hemoglobin (HbA1c)
Tidsram: From baseline to Day 180.

Glycated hemoglobin measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Fasting insulin level
Tidsram: From baseline to Day 180.

Fasting serum insulin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
HOMA-IR
Tidsram: From baseline to Day 180.

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin values.

From baseline to Day 180.
Total cholesterol level
Tidsram: From baseline to Day 180.

Total cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
HDL cholesterol level
Tidsram: From baseline to Day 180.

HDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
LDL cholesterol level
Tidsram: From baseline to Day 180.

LDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Triglyceride level
Tidsram: From baseline to Day 180.

Serum triglyceride concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Aspartate aminotransferase (AST) level
Tidsram: From baseline to Day 180.

AST concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Alanine aminotransferase (ALT) level
Tidsram: From baseline to Day 180.

ALT concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Gamma-glutamyl transferase (GGT) level
Tidsram: From baseline to Day 180.

GGT concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Blood urea level
Tidsram: From baseline to Day 180.

Blood urea concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum creatinine level
Tidsram: From baseline to Day 180.

Serum creatinine concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Self-assessment questionnaire
Tidsram: From baseline to Day 180.

Subject-reported perception of hair condition assessed using a 12-item questionnaire covering perceived hair density, hair shedding, hair strength, hair volume, appearance, and scalp condition. Each item is rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate greater perceived improvement in hair and scalp condition.

From baseline to Day 180.
Food consumption frequency questionnaire (PREDIMED questionnaire)
Tidsram: From baseline to Day 180.

Adherence to the Mediterranean diet assessed using the validated 14-item PREDIMED (Prevención con Dieta Mediterránea) questionnaire. The questionnaire evaluates the frequency of consumption of key food groups and dietary habits characteristic of the Mediterranean diet, including olive oil use, fruit and vegetable intake, legumes, fish, nuts, red meat, sugary beverages, commercial pastries, and wine consumption. Each item is scored 0 or 1, resulting in a total score ranging from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet.

From baseline to Day 180.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

16 mars 2026

Primärt slutförande (Beräknad)

31 maj 2027

Avslutad studie (Beräknad)

31 augusti 2027

Studieregistreringsdatum

Först inskickad

9 mars 2026

Först inskickad som uppfyllde QC-kriterierna

17 mars 2026

Första postat (Faktisk)

19 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera